Evidence map›Paper›PMID 26601340›Full record

ReviewScience progress2015

Between pathways and networks lies context: implications for precision medicine.

Ted Laderas, Guanming Wu, Shannon McWeeney

Abstract readReview
In one paragraph

Review in Science progress, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ted Laderas
Guanming Wu
Shannon McWeeney

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine, broadly defined as considering individual variability in genes, environment, and lifestyle for each person in disease prevention and selection of suitable medical intervention, shows strong promise in the treatment of cancer Selecting therapies is complicated by multiple routes to gene dysregulation, which manifest in the individual patient within the many different types of genomic measurements. Additionally, multiple mutations exist in patients, aphenomenon known as oncogenic collaboration, which further complicates the selection of therapy. In this article, we discuss current approaches using biological pathways and networks to unify the many types of OMICs data. We argue that a contextual approach combining cancer pathways and networks could lead to a proper understanding of the biology of this significant disease.

Indexed as

Gene Regulatory NetworksAnimalsHumansMetabolic Networks and PathwaysNeoplasmsPrecision Medicine

Identifiers

PMID26601340
PMCPMC10365530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.